ADC on the Edge: The Struggles of Chinese Pharmaceutical Companies Amid Technical Shortcomings and Capital Withdrawal
This March, the American biotechnology company Elevation Oncology announced the termination of the development pipeline for EO-3021 (Claudin 18.2 ADC) licensed from Shiyao Group, redirecting resources to EO-1022 (HER-3 ADC).In July 2022, Shiyao Group licensed EO-3021 to Elevation, which paid a $27 million upfront fee along with potential milestone payments of up to $1.148 billion … Read more